Biogen (BIIB) Total Non-Current Liabilities (2009 - 2026)
Biogen (BIIB) posted quarterly Total Non-Current Liabilities of $12.4 billion for Q2 2026, up 25.47% year-over-year from $9.9 billion in Q2 2025, and up 23.63% quarter-over-quarter from $10.0 billion in Q1 2026.
Biogen (BIIB) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Biogen's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $12.4 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 25.47% year-over-year to $12.4 billion; the TTM figure through Jun 2026 stood at $12.4 billion (up 25.47% YoY), while the FY2025 annual figure was $10.4 billion, down 1.57% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $12.4 billion, up from $10.0 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $13.0 billion in Q3 2023, with the low at $9.9 billion in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $10.5 billion (2024), against an average of $10.8 billion.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities retreated 17.68% in 2023, then advanced 25.47% in 2026.
- Biogen's Total Non-Current Liabilities stood at $10.2 billion in 2022, then gained by 10.2% to $11.3 billion in 2023, then declined by 5.89% to $10.6 billion in 2024, then dropped by 1.57% to $10.4 billion in 2025, then rose by 19.01% to $12.4 billion in 2026.
- Business Quant data shows BIIB's Total Non-Current Liabilities at $12.4 billion in Q2 2026, $10.0 billion in Q1 2026, and $10.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 12.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.42 Bn |
| Mar 31, 2026 | 10.04 Bn |
| Dec 31, 2025 | 10.43 Bn |
| Sep 30, 2025 | 10.24 Bn |
| Jun 30, 2025 | 9.90 Bn |
| Mar 31, 2025 | 10.30 Bn |
| Dec 31, 2024 | 10.60 Bn |
| Sep 30, 2024 | 11.21 Bn |
| Jun 30, 2024 | 10.36 Bn |
| Mar 31, 2024 | 10.58 Bn |
| Dec 31, 2023 | 11.26 Bn |
| Sep 30, 2023 | 12.97 Bn |
| Jun 30, 2023 | 9.92 Bn |
| Mar 31, 2023 | 9.88 Bn |
| Dec 31, 2022 | 10.22 Bn |
| Sep 30, 2022 | 10.89 Bn |
| Jun 30, 2022 | 12.05 Bn |
| Mar 31, 2022 | 11.11 Bn |
| Dec 31, 2021 | 11.60 Bn |
| Sep 30, 2021 | 11.61 Bn |